LIGAND PHARMACEUTICALS INC (LGND) - Dilution Analysis
Visualizing historical and potential share dilution over time
Dilution Analysis
Risk Assessment Details
Summary
LGND currently has 19.6M outstanding shares. with minimal authorized share overhang for future dilution. The company has minimally diluted shareholders by 9.1% over the past 2 years.
Share Structure Timeline
Historical Data Points
| Date | Event | Outstanding | Supply |
|---|---|---|---|
| Nov 07, 2025 |
10-Q filing | 19.6M shares outstanding |
20M | 0 |
| Aug 08, 2025 |
10-Q filing | 19.3M shares outstanding |
19M | 0 |
| May 09, 2025 |
10-Q filing | 19.2M shares outstanding |
19M | 0 |
| Feb 28, 2025 |
10-K filing | 18.3M shares outstanding |
18M | 0 |
| Nov 08, 2024 |
10-Q filing | 18.4M shares outstanding |
18M | 0 |
| Aug 07, 2024 |
10-Q filing | 18.0M shares outstanding |
18M | 0 |
| May 08, 2024 |
10-Q filing | 18.1M shares outstanding |
18M | 0 |
| May 07, 2024 |
8-K filing: Ligand Pharmaceuticals Incorporated entered into a Purchase and Sale Agreement with Agenus Inc. to obtain certain royalty rights for an aggregate purchase price of $75 million and Agenus Inc. issued to Ligand a warrant to purchase 867,052 shares of its common stock at an exercise price equal to $17.30. |
18M | 0 |
| Feb 29, 2024 |
10-K filing | 17.8M shares outstanding |
18M | 0 |
| Nov 09, 2023 |
10-Q filing | 17.4M shares outstanding |
17M | 0 |
| Aug 09, 2023 |
10-Q filing | 17.3M shares outstanding |
17M | 0 |
| May 08, 2023 |
10-Q filing | 17.1M shares outstanding |
17M | 0 |
| Feb 28, 2023 |
10-K filing | 16.9M shares outstanding |
17M | 0 |
| Nov 08, 2022 |
10-Q filing | 16.9M shares outstanding |
17M | 0 |
| Aug 09, 2022 |
10-Q filing | 16.9M shares outstanding |
17M | 0 |
| May 09, 2022 |
10-Q filing | 16.8M shares outstanding |
17M | 0 |
| Feb 28, 2022 |
10-K filing | 16.6M shares outstanding |
17M | 0 |
| Nov 09, 2021 |
10-Q filing | 16.7M shares outstanding |
17M | 0 |
| Aug 03, 2021 |
10-Q filing | 16.7M shares outstanding |
17M | 0 |
| May 06, 2021 |
10-Q filing | 16.4M shares outstanding |
16M | 0 |
| Feb 24, 2021 |
10-K filing | 16.2M shares outstanding |
16M | 0 |
| Nov 06, 2020 |
10-Q filing | 16.1M shares outstanding |
16M | 0 |
| Aug 07, 2020 |
10-Q filing | 16.1M shares outstanding |
16M | 0 |
| May 08, 2020 |
10-Q filing | 16.5M shares outstanding |
17M | 0 |
| Apr 06, 2020 |
8-K filing: The Company repurchased approximately 473,000 shares of its common stock for approximately $37 million pursuant to its previously announced $500 million stock repurchase program during the quarter ended March 31, 2020. ($37.0M proceeds) |
17M | 0 |
| Feb 27, 2020 |
10-K filing | 16.5M shares outstanding |
17M | 0 |